Bharat Parenterals' subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the U.S.

FDA for its Vadodara finished dosage manufacturing facility.

This signifies successful clearance of the U.S.

FDA inspection, enabling acceptance of the site for commercial operations for products under inspection.

This milestone reinforces Innoxel’s commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as the United States and the European Union.